Travel distance to tertiary sarcoma centres does not influence oncological presentation or outcomes

  • A. Gazendam
  • , L. Zhang
  • , D. Clever
  • , A. Griffin
  • , J. Wunder
  • , P. Ferguson
  • , K. M. Tsoi

Research output: Contribution to journalArticlepeer-review

Abstract

Aims Soft-tissue sarcomas (STSs) are rare cancers with centralized care advocated to consolidate resources and expertise. However, geographical challenges, particularly in countries like Canada, can increase travel distances for patients.The impact of travel distance on sarcoma presentation and outcomes remains unclear, particularly in single-payer healthcare systems with centralized care. Methods A retrospective cohort analysis was conducted on 1,570 patients with STS who underwent surgical resection at a Canadian tertiary referral centre between January 2010 and January 2021. Patients were divided into those living ≤ 50 km and > 50 km from the centre. Demographics, tumour characteristics, treatment methods, and survival outcomes were analyzed. A Cox regression model was constructed to evaluate predictors of overall survival. Results Patients living > 50 km from the centre (n = 700) travelled a mean of 176 km (SD 250), while those ≤ 50 km (n = 870) travelled a mean of 24.8 km (SD 13.8).There were no significant differences in disease presentation, time to definitive treatment, use of systemic therapies, or functional outcomes between the two groups.The two-year and five-year overall survival rates were similar between the groups (83.1% (95% CI 80.1% to 86.1%) vs 83.8% (95% CI 81.8% to 85.8%) and 72.1% (95% CI 69.1% to 75.1%) vs 72.5% (95% CI 69.5% to 75.5%), respectively).The regression model demonstrated that age, higher tumour grade, depth, and lower income were predictive of worse overall survival, while distance travelled was not an independent predictor of survival. Conclusion Contrary to previous studies, our findings suggest that travel distance did not influence disease presentation or survival outcomes in STS patients treated at a centralized sarcoma centre.This challenges previous notions regarding the impact of travel distance on cancer outcomes, and supports the effectiveness of centralized care models, even in geographically vast regions.

Original languageEnglish
Pages (from-to)368-372
Number of pages5
JournalBone and Joint Journal
Volume107 B
Issue number3
DOIs
StatePublished - Mar 2025

Fingerprint

Dive into the research topics of 'Travel distance to tertiary sarcoma centres does not influence oncological presentation or outcomes'. Together they form a unique fingerprint.

Cite this